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Abstract
Approximately 4,000 children in the United States are diagnosed annually
with a brain tumor. Brain cancers are the deadliest of all pediatric cancers as
they have survival rates of less than 20%. Although surgery and radiation
therapy are widely used to treat adult patients, chemotherapy is the primary
therapeutic option for children. One important chemotherapeutic agent is
temozolomide, an alkylating agent that causes cell death by damaging DNA.
In this project, we tested the ability of a specific non-natural nucleoside
developed in our lab, designated 5-NIdR, to increase the efficacy of
temozolomide against brain cancer. Cell-based studies demonstrate that the
combination of 5-NIdR and temozolomide kills more cells compared to
treatment with either temozolomide or 5-NIdR used alone. Microscopy
techniques demonstrate that the combination of 5-NIdR and temozolomide
causes cell death via apoptosis rather than necrosis. Animal studies using
xenograft (nude) mice were performed to evaluate the in vivo efficacy and
safety of this drug combination against brain cancer. Preliminary results are
provided which indicate that treatment with 5-NIdR does not inhibit the rate
of tumor growth. In contrast, treatment with temozolomide reduces the rate
of tumor growth but does not lead to the complete elimination of the tumor.
Striking results are obtained using 5-NIdR and temozolomide together as
this drug combination causes a significant reduction in tumor size. Finally,
mice treated with the combination of 5-NIdR and temozolomide do not show
overt signs of side effects such as weight loss, dehydration, or fatigue.
Collectively, these studies provide pharmacological evidence for combining
5-NIdR and temozolomide as a new treatment strategy to effectively treat
brain cancers.
*

	
  

Post-doctoral Fellow

